{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:23:22Z","timestamp":1785875002248,"version":"3.56.0"},"reference-count":41,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan","award":["BR10965271"],"award-info":[{"award-number":["BR10965271"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In Central Eurasia, the availability of drugs that are inhibitors of the SARS-CoV-2 virus and have proven clinical efficacy is still limited. The aim of this study was to evaluate the activity of drugs that were available in Kazakhstan during the acute phase of the epidemic against SARS-CoV-2. Antiviral activity is reported for Favipiravir, Tilorone, and Cridanimod, which are registered drugs used for the treatment of respiratory viral infections in Kazakhstan. A licorice (Glycyrrhiza glabra) extract was also incorporated into this study because it offered an opportunity to develop plant-derived antivirals. The Favipiravir drug, which had been advertised in local markets as an anti-COVID cure, showed no activity against SARS-CoV-2 in cell cultures. On the contrary, Cridanimod showed impressive high activity (median inhibitory concentration 66 \u03bcg\/mL) against SARS-CoV-2, justifying further studies of Cridanimod in clinical trials. Tilorone, despite being in the same pharmacological group as Cridanimod, stimulated SARS-CoV-2 replication in cultures. The licorice extract inhibited SARS-CoV-2 replication in cultures, with a high median effective concentration of 16.86 mg\/mL. Conclusions: The synthetic, low-molecular-weight compound Cridanimod suppresses SARS-CoV-2 replication at notably low concentrations, and this drug is not toxic to cells at therapeutic concentrations. In contrast to its role as an inducer of interferons, Cridanimod is active in cells that have a genetic defect in interferon production, suggesting a different mechanism of action. Cridanimod is an attractive drug for inclusion in clinical trials against SARS-CoV-2 and, presumably, other coronaviruses. The extract from licorice shows low activity against SARS-CoV-2. At the same time, high doses of 2 g\/kg of this plant extract show little or no acute toxicity in animal studies; for this reason, licorice products can still be considered for further development as a safe, orally administered adjunctive therapy.<\/jats:p>","DOI":"10.3390\/molecules28166142","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:46:56Z","timestamp":1692582416000},"page":"6142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked"],"prefix":"10.3390","volume":"28","author":[{"given":"Murat Zh.","family":"Zhurinov","sequence":"first","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfira F.","family":"Miftakhova","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"},{"name":"Faculty of Chemistry and Chemical Technology, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Keyer","sequence":"additional","affiliation":[{"name":"Laboratory for Genetic Engineering, RSE \u201cNational Center for Biotechnology\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-0816","authenticated-orcid":false,"given":"Zarina T.","family":"Shulgau","sequence":"additional","affiliation":[{"name":"Laboratory for Genetic Engineering, RSE \u201cNational Center for Biotechnology\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Solodova","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"},{"name":"Department of Biochemical Engineering, International Engineering Technological University, Almaty 050040, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-441X","authenticated-orcid":false,"given":"Maxat K.","family":"Kalykberdiyev","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlan Z.","family":"Abilmagzhanov","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-4765","authenticated-orcid":false,"given":"Eldar T.","family":"Talgatov","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sauyk","family":"Ait","sequence":"additional","affiliation":[{"name":"\u201cD.V. Sokolskiy Institute of Fuel, Catalysis and Electrochemistry\u201d JSC, Almaty 050010, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9382","authenticated-orcid":false,"given":"Alexandr V.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Laboratory for Genetic Engineering, RSE \u201cNational Center for Biotechnology\u201d, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"ref_1","first-page":"5","article-title":"COVID-19 in Kazakhstan: Economic consequences and policy implications","volume":"234","author":"Ybrayev","year":"2020","journal-title":"CAP PAPER"},{"key":"ref_2","unstructured":"(2023, August 04). COVID-19 Crisis Response in Central Asia. Available online: https:\/\/www.oecd.org\/coronavirus\/policy-responses\/covid-19-crisis-response-in-central-asia-5305f172\/."},{"key":"ref_3","unstructured":"(2023, August 04). Electronic Source. Available online: https:\/\/covid19.trackvaccines.org\/country\/kazakhstan\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101091","DOI":"10.1016\/j.ehb.2021.101091","article-title":"Effectiveness of social distancing interventions in containing COVID-19 incidence: International evidence using Kalman filter","volume":"44","author":"Prakash","year":"2022","journal-title":"Econ. Hum. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105596","DOI":"10.1016\/j.isci.2022.105596","article-title":"Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models","volume":"25","author":"Takeshita","year":"2022","journal-title":"iScience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.24875\/AIDSRev.22000001","article-title":"Oral antivirals for the prevention and treatment of SARS-CoV-2 infection","volume":"24","author":"Soriano","year":"2022","journal-title":"AIDS Rev."},{"key":"ref_8","unstructured":"World Health Organization (2023). Therapeutics and COVID-19: Living Guideline, 13 January 2023."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nemyatykh, O.D., Maistrenko, M.A., Demchenko, D.D., Narkevich, I.A., Okovityi, S.V., and Timchenko, V.N. (2023). Principles of Rational COVID-19 Therapy in Pediatrics. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144731"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3906\/sag-2008-33","article-title":"Treatment of SARS-CoV-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey","volume":"51","author":"Erdem","year":"2021","journal-title":"Turk. J. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107702","DOI":"10.1016\/j.intimp.2021.107702","article-title":"Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial","volume":"97","author":"Zhao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e02017-20","DOI":"10.1128\/AAC.02017-20","article-title":"Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)","volume":"64","author":"McCullough","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jep.2013.04.040","article-title":"Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines","volume":"148","author":"Wang","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Diomede, L., Beeg, M., Gamba, A., Fumagalli, O., Gobbi, M., and Salmona, M. (2021). Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?. Biomolecules, 11.","DOI":"10.3390\/biom11060855"},{"key":"ref_15","unstructured":"COVID-19 Treatment Guidelines Panel (2023, July 27). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32366720","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1038\/s41598-022-08794-w","article-title":"Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild\/moderate COVID-19 disease","volume":"12","author":"Kumar","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-020-02799-8","article-title":"Tilorone: A Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond","volume":"37","author":"Ekins","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01711","DOI":"10.1128\/AAC.01711-17","article-title":"Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection. Antimicrob","volume":"62","author":"Ekins","year":"2018","journal-title":"Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/srep18035","article-title":"Rat and human STINGs profile similarly towards anticancer\/antiviral compounds","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/AAC.9.2.233","article-title":"Antiviral activity of 10-carboxymethyl-9-acridanone","volume":"9","author":"Kramer","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","first-page":"216","article-title":"Failure of high doses of potentially antiviral agents to prevent death in virus-infected mice","volume":"29","author":"Veckenstedt","year":"1985","journal-title":"Acta Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Keyer, V., Syzdykova, L., Zauatbayeva, G., Zhulikeyeva, A., Ramanculov, Y., Shustov, A.V., and Shulgau, Z. (2022). Tilorone and Cridanimod Protect Mice and Show Antiviral Activity in Rats despite Absence of the Interferon-Inducing Effect in Rats. Pharmaceuticals, 17.","DOI":"10.3390\/ph15050617"},{"key":"ref_27","first-page":"7454","article-title":"Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms","volume":"6","author":"Puhl","year":"2020","journal-title":"bioRxiv"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18240","DOI":"10.1038\/s41598-019-54208-9","article-title":"Meglumine acridone acetate, the ionic salt of CMA and N-methylglucamine, induces apoptosis in human PBMCs via the mitochondrial pathway","volume":"9","author":"Plotnikova","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_29","first-page":"a013227","article-title":"Endoplasmic reticulum structure and interconnections with other organelles","volume":"5","author":"English","year":"2013","journal-title":"Rev. Cold Spring Harb. Perspect. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.12688\/f1000research.73170.2","article-title":"Evidence of mitochondria origin of SARS-CoV-2 double-membrane vesicles: A review. [version 2; peer review: 1 approved]","volume":"10","year":"2022","journal-title":"F1000Research"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yang, X., Wan, M., Cai, L., Hou, A., Sun, B., Zhou, Y., Gao, F., Su, W., and Jiang, C. (2021). Interferon Inhibition Enhances the Pilot-Scale Production of Rabies Virus in Human Diploid MRC-5 Cells. Viruses, 14.","DOI":"10.3390\/v14010049"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1080\/07391102.2020.1779132","article-title":"Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: A pharmacoinformatics study","volume":"39","author":"Sinha","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wahab, S., Annadurai, S., Abullais, S.S., Das, G., Ahmad, W., Ahmad, M.F., Kandasamy, G., Vasudevan, R., Ali, M.S., and Amir, M. (2021). Glycyrrhiza glabra (Licorice): A Comprehensive Review on Its Phytochemistry, Biological Activities, Clinical Evidence and Toxicology. Plants, 10.","DOI":"10.3390\/plants10122751"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1016\/j.matpr.2020.10.055","article-title":"Molecular docking and ADMET study of bioactive compounds of Glycyrrhiza glabra against main protease of SARS-CoV2","volume":"49","author":"Srivastava","year":"2020","journal-title":"Mater. Today Proc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.apsb.2015.05.005","article-title":"The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb","volume":"5","author":"Wang","year":"2015","journal-title":"Acta Pharm. Sin."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Abraham, J., and Florentine, S. (2021). Licorice (Glycyrrhiza glabra) Extracts-Suitable Pharmacological Interventions for COVID-19? A Review. Plants, 10.","DOI":"10.3390\/plants10122600"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12985-021-01587-z","article-title":"Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives","volume":"18","author":"Yan","year":"2021","journal-title":"Virol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2001410","DOI":"10.2807\/1560-7917.ES.2020.25.32.2001410","article-title":"Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020","volume":"25","author":"Alm","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virol.2020.05.015","article-title":"Growth, detection, quantification, and inactivation of SARS-CoV-2","volume":"548","author":"Case","year":"2020","journal-title":"Virology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Brandolini, M., Taddei, F., Marino, M.M., Grumiro, L., Scalcione, A., Turba, M.E., Gentilini, F., Fantini, M., Zannoli, S., and Dirani, G. (2021). Correlating qRT-PCR, dPCR and viral titration for the identification and quantification of sars-cov-2: A new approach for infection management. Viruses, 13.","DOI":"10.3390\/v13061022"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Postnikova, E., Cong, Y., DeWald, L.E., Dyall, J., Yu, S., Hart, B.J., Zhou, H., Gross, R., Logue, J., and Cai, Y. (2018). Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194880"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/16\/6142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:37:41Z","timestamp":1760128661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/16\/6142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":41,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["molecules28166142"],"URL":"https:\/\/doi.org\/10.3390\/molecules28166142","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]}}}